A Study of Anakinra in Japanese Patients With Still's Disease (SJIA and AOSD)

Key facts

Sponsor

Swedish Orphan Biovitrum

Principal Investigator

Masaaki Mori, MD

St. Marianna University Hospital

Intervention

Anakinra(drug)

Enrollment

15 enrolled

Eligibility

8 years · All sexes

Timeline

2022 – 2025

Study locations (8)

• Fukushima Medical University Hospital, Fukushima, Fukushima, Japan
• Hyogo Prefectural Kobe Children's Hospital, Kobe, Hyōgo, Japan
• Kobe University Hospital, Kobe, Hyōgo, Japan
• Yokohama City University Hospital (Hematology and Clinical Immunology), Yokohama, Kanagawa, Japan
• Shinshu University, Matsumoto, Nagano, Japan
• Tokyo Medical And Dental University Hospital, Bunkyō-Ku, Tokyo, Japan
• Tokyo Women's Medical University Hospital, Shinjuku-Ku, Tokyo, Japan
• Gifu University Hospital, Gifu, Japan

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Adult-onset Still disease

Additional recruiting or active studies for the same condition.

• RECRUITINGPHASE2NCT07203001
  A Phase II Trial to Evaluate the Clinical Efficacy, Safety and Tolerability of MAS825 in Pediatric and Adult Participants With Still's Disease
  Novartis Pharmaceuticals
• RECRUITINGNCT04402086
  Rheumatology Patient Registry and Biorepository
  Yale University
• RECRUITINGNCT03510442
  Natural History, Genetics, and Pathophysiology of Systemic Juvenile Idiopathic Arthritis, Adult-Onset Still's Disease, and Related Conditions
  National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
• RECRUITINGNCT05927454
  Acostill ( RaDiCo Cohort) (RaDiCo Acostill)
  Institut National de la Santé Et de la Recherche Médicale, France
• RECRUITINGNCT02143986
  Glycosylated Ferritin in Macrophagic Activation Syndromes
  Brugmann University Hospital

See all trials for Adult-onset Still disease →